Myelodysplastic Syndromes
September 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Authors:Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, Deotare U, Michelis FV
Institution:Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. Fotios.Michelis@uhn.ca.
Journal:Ann Hematol. 2018 Oct;97(10):1975-1985. doi: 10.1007/s00277-018-3391-9. Epub 2018 Jun 11.

2:Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome: A case report and literature review.
Authors:Sun C, Luo Y, Tong H, Xu G, Lin J
Institution:Department of Rheumatology. Zhejiang University, Hangzhou, China. Zhejiang University, Hangzhou, China.
Journal:Medicine (Baltimore). 2018 Jun;97(25):e11179. doi: 10.1097/MD.0000000000011179.

3:Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Authors:Castelli R, Schiavon R, Rossi V, Deliliers GL
Institution:Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital Milan, University of Milan, Milan, Italy. roberto.castelli@unimi.it. Milan, University of Milan, Milan, Italy. L. Sacco University Hospital, University of Milan, Milan, Italy.
Journal:Med Oncol. 2018 Apr 19;35(5):76. doi: 10.1007/s12032-018-1135-2.

4:Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Authors:Montoro J, Gallur L, Merchan B, Molero A, Roldan E, Martinez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellvi J, Saumell S, Bobillo S, Bosch F, Valcarcel D
Institution:Department of Hematology, University Hospital Vall d'Hebron, University Autonoma of Barcelona (UAB), Barcelona, Spain. dvalcarcel@vhio.net.; Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. dvalcarcel@vhio.net.; Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.; Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Journal:Ann Hematol. 2018 Aug;97(8):1349-1356. doi: 10.1007/s00277-018-3302-0. Epub 2018 Mar 23.

5:Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.
Authors:Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, Haase D
Institution:Department of Hematology and Medical Oncology, University Medicine Gottingen (UMG), Gottingen, Germany. julie.schanz@med.uni-goettingen.de. (UMG), Gottingen, Germany. Germany. (UMG), Gottingen, Germany. (UMG), Gottingen, Germany. Switzerland. (UMG), Gottingen, Germany.
Journal:Blood Cancer J. 2018 Mar 7;8(3):28. doi: 10.1038/s41408-018-0061-z.

6:Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Authors:Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, Li M, Zhan X, Li W
Institution:Department of Hematology, The First Hospital of Jilin University, Changchun, China. China. China. China. China. Electronic address: jdyylw@163.com.
Journal:Crit Rev Oncol Hematol. 2018 Feb;122:123-132. doi: 10.1016/j.critrevonc.2017.12.013. Epub 2018 Jan 3.

7:Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
Authors:Shimomura Y, Hara M, Katoh D, Hashimoto H, Ishikawa T
Institution:Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, chuo-ku, Kobe, 650-0047, Japan. shimomura_0119@yahoo.co.jp.; Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.; Department of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Journal:Ann Hematol. 2018 Jun;97(6):1049-1056. doi: 10.1007/s00277-018-3278-9. Epub 2018 Feb 17.

8:The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Authors:Castelli R, Schiavon R, Deliliers GL
Institution:Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Luigi Sacco Hospital Milan, Milan, Italy. roberto.castelli@unimi.it.
Journal:Med Oncol. 2018 Feb 8;35(3):33. doi: 10.1007/s12032-018-1094-7.

9:Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Authors:Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hkantarjian@mdanderson.org. Louis, Universite Paris 7, Paris, France. University of Melbourne, Melbourne, Australia. Medizinische Klinik und Poliklinik I, Dresden, Germany. klinische Immunologie, Heinrich-Heine-University of Dusseldorf, Medizinische Klinik und Poliklinik A, Dusseldorf, Germany. Eastern Piedmont, Novara, Italy. Dusseldorf, Germany.
Journal:Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26.

10:Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Authors:Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF
Institution:Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: rami.komrokji@moffitt.org. Houston, TX, USA. Medicine, New Haven, CT, USA. USA. Medical Center, New York, NY, USA. Toulouse, France. MD, USA. Houston, TX, USA. Tampa, FL, USA.
Journal:Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

11:Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study.
Authors:Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL
Institution:Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangdong General Hospital affiliated to South China University of Technology, Guangdong, China. Beijing, China. Sciences and Peking Union Medical College, Tianjin, China. China. University of Science and Technology, Wuhan, China. Suzhou, China. College of Medicine, Zhejiang, China.
Journal:Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28.

12:Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Authors:Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D
Institution:Tel Aviv Sourasky Medical Center, Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel. Electronic address: moshemt@tlvmc.gov.il. Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.
Journal:Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11.

13:Iron overload in myelodysplastic syndromes (MDS).
Authors:Gattermann N
Institution:Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany. gattermann@med.uni-duesseldorf.de.
Journal:Int J Hematol. 2018 Jan;107(1):55-63. doi: 10.1007/s12185-017-2367-1. Epub 2017 Nov 25.

14:Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Authors:Schroeder T, Rautenberg C, Kruger W, Platzbecker U, Bug G, Steinmann J, Klein S, Hopfer O, Nachtkamp K, Kondakci M, Geyh S, Haas R, Germing U, Bornhauser M, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.; Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.; Department of Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.; Med. Clinic III, University Medicine Mannheim, Mannheim, Germany.
Journal:Ann Hematol. 2018 Feb;97(2):335-342. doi: 10.1007/s00277-017-3185-5. Epub 2017 Nov 18.

15:Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Authors:Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G
Institution:Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Dusseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.
Journal:Int J Hematol. 2018 Feb;107(2):138-150. doi: 10.1007/s12185-017-2364-4. Epub 2017 Nov 15.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 4, 2018
227 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS53178809

Coupon Expires: October 20, 2018



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.